• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Thiopurines are an independent risk factor for active tuberculosis in inflammatory bowel disease patients.硫嘌呤类药物是炎症性肠病患者发生活动性结核病的一个独立危险因素。
World J Gastroenterol. 2023 Mar 7;29(9):1536-1538. doi: 10.3748/wjg.v29.i9.1536.
2
Thiopurines related malignancies in inflammatory bowel disease: local experience in Granada, Spain.炎症性肠病相关的硫嘌呤类药物相关性恶性肿瘤：西班牙格拉纳达的本地经验。
World J Gastroenterol. 2013 Aug 14;19(30):4877-86. doi: 10.3748/wjg.v19.i30.4877.
3
Canadian Association of Gastroenterology position statement regarding the use of thiopurines for the treatment of inflammatory bowel disease.加拿大胃肠病学协会关于使用硫唑嘌呤治疗炎症性肠病的立场声明。
Can J Gastroenterol Hepatol. 2014 Jul-Aug;28(7):371-2. doi: 10.1155/2014/649465.
4
Safety of thiopurines in the treatment of inflammatory bowel disease.硫唑嘌呤类药物治疗炎症性肠病的安全性
Scand J Gastroenterol Suppl. 2003(239):69-72. doi: 10.1080/00855920310002726.
5
Risk of lymphoma in patients with inflammatory bowel disease treated with azathioprine and 6-mercaptopurine: a meta-analysis.炎症性肠病患者应用硫唑嘌呤和 6-巯基嘌呤治疗后发生淋巴瘤的风险：一项荟萃分析。
Clin Gastroenterol Hepatol. 2015 May;13(5):847-58.e4; quiz e48-50. doi: 10.1016/j.cgh.2014.05.015. Epub 2014 May 28.
6
Systematic review and meta-analysis on the effects of thiopurines on birth outcomes from female and male patients with inflammatory bowel disease.系统评价和荟萃分析噻嘌呤类药物对女性和男性炎症性肠病患者生育结局的影响。
Inflamm Bowel Dis. 2013 Jan;19(1):15-22. doi: 10.1002/ibd.22948.
7
Review article: the treatment of inflammatory bowel disease with 6-mercaptopurine or azathioprine.综述文章：6-巯基嘌呤或硫唑嘌呤治疗炎症性肠病
Aliment Pharmacol Ther. 2001 Nov;15(11):1699-708. doi: 10.1046/j.1365-2036.2001.01102.x.
8
Decrease in factor V activity: a new adverse effect of purine analogs in inflammatory bowel diseases?因子V活性降低：嘌呤类似物在炎症性肠病中的一种新的不良反应？
Inflamm Bowel Dis. 2008 Jul;14(7):1024-5. doi: 10.1002/ibd.20411.
9
Thiopurines in Inflammatory Bowel Disease: New Findings and Perspectives.炎症性肠病中的硫嘌呤：新发现与新视角。
J Crohns Colitis. 2018 Apr 27;12(5):610-620. doi: 10.1093/ecco-jcc/jjx181.
10
Azathioprine or 6-mercaptopurine for inflammatory bowel disease: do risks outweigh benefits?硫唑嘌呤或6-巯基嘌呤用于治疗炎症性肠病：风险是否大于益处？
Dig Liver Dis. 2000 Aug-Sep;32(6):518-31. doi: 10.1016/s1590-8658(00)80010-9.

引用本文的文献

1
Case Report: Macrophage activation syndrome due to multifocal tuberculosis in an immunocompromised patient.病例报告：免疫功能低下患者因多灶性结核病引发巨噬细胞活化综合征。
F1000Res. 2025 Apr 17;13:1439. doi: 10.12688/f1000research.158982.2. eCollection 2024.
2
Azathioprine monotherapy withdrawal in inflammatory bowel diseases: A retrospective mono-centric study.炎症性肠病中单用硫唑嘌呤治疗的撤药：一项回顾性单中心研究。
World J Gastroenterol. 2023 Jul 21;29(27):4334-4343. doi: 10.3748/wjg.v29.i27.4334.

本文引用的文献

1
ECCO Guidelines on the Prevention, Diagnosis, and Management of Infections in Inflammatory Bowel Disease.欧洲克罗恩病和结肠炎组织（ECCO）关于炎症性肠病感染的预防、诊断和管理指南
J Crohns Colitis. 2021 Jun 22;15(6):879-913. doi: 10.1093/ecco-jcc/jjab052.
2
Active tuberculosis in inflammatory bowel disease patients under treatment from an endemic area in Latin America.拉丁美洲流行地区治疗中炎症性肠病患者的活动性肺结核。
World J Gastroenterol. 2020 Nov 28;26(44):6993-7004. doi: 10.3748/wjg.v26.i44.6993.
3
Biologics for the Management of Inflammatory Bowel Disease: A Review in Tuberculosis-Endemic Countries.用于炎症性肠病管理的生物制剂：在结核病流行国家的综述。
Gut Liver. 2020 Nov 15;14(6):685-698. doi: 10.5009/gnl19209.
4
Asian Organization for Crohn's and Colitis and Asia Pacific Association of Gastroenterology practice recommendations for medical management and monitoring of inflammatory bowel disease in Asia.亚洲克罗恩病和结肠炎组织与亚太消化病学会炎症性肠病亚洲地区医学管理和监测实践建议。
J Gastroenterol Hepatol. 2021 Mar;36(3):637-645. doi: 10.1111/jgh.15185. Epub 2020 Jul 29.
5
Risk of Tuberculosis in Patients With Inflammatory Bowel Disease on Infliximab or Adalimumab Is Dependent on the Local Disease Burden of Tuberculosis: A Systematic Review and Meta-Analysis.英夫利昔单抗或阿达木单抗治疗炎症性肠病患者的结核发病风险取决于当地结核病负担：系统评价和荟萃分析。
Am J Gastroenterol. 2020 Mar;115(3):340-349. doi: 10.14309/ajg.0000000000000527.
6
Asian Organization for Crohn's and Colitis and Asia Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti-tumor necrosis factor treatment. Part 1: risk assessment.亚洲克罗恩病和结肠炎组织及亚太胃肠病学协会关于接受抗肿瘤坏死因子治疗的炎症性肠病患者结核感染的共识。第1部分：风险评估。
Intest Res. 2018 Jan;16(1):4-16. doi: 10.5217/ir.2018.16.1.4. Epub 2018 Jan 18.
7
Risk of tuberculosis after lung transplantation: the value of pretransplant chest computed tomography and the impact of mTOR inhibitors and azathioprine use.肺移植术后肺结核的风险：移植前胸部计算机断层扫描的价值以及雷帕霉素靶蛋白抑制剂和硫唑嘌呤使用的影响
Transpl Infect Dis. 2016 Aug;18(4):512-9. doi: 10.1111/tid.12555. Epub 2016 Aug 2.
8
Tuberculous pleurisy: an unusual complication during treatment of Crohn disease with azathioprine.结核性胸膜炎：硫唑嘌呤治疗克罗恩病期间的一种罕见并发症。
Scand J Gastroenterol. 2001 Sep;36(9):1004-7.

硫嘌呤类药物是炎症性肠病患者发生活动性结核病的一个独立危险因素。

Thiopurines are an independent risk factor for active tuberculosis in inflammatory bowel disease patients.

机构信息

Ciências da Vida, Universidade do Estado da Bahia, Salvador 41150000, Brazil, and Programa de Pós-Graduação em Medicina e Saúde, Universidade Federal da Bahia, Salvador 40110060, Brazil.

Ciência da Nutrição, Universidade Federal da Bahia, Salvador 40110160, Brazil.

出版信息

World J Gastroenterol. 2023 Mar 7;29(9):1536-1538. doi: 10.3748/wjg.v29.i9.1536.

DOI:10.3748/wjg.v29.i9.1536
PMID:36998430
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10044854/
Abstract

The use of thiopurines is an independent risk factor for active tuberculosis in patients with inflammatory bowel disease.

摘要

硫嘌呤类药物的使用是炎症性肠病患者发生活动性结核病的一个独立危险因素。